Initiate second STS101 Phase 3 efficacy trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 31 Jul 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The updated STS101 development plan includes a new Phase 3 efficacy trial, which the Company anticipates initiating in mid-2021”
What we found
Evidence strength A What the grades mean
Later filings state the new SUMMIT Phase 3 efficacy trial was initiated in June 2021, before the mid-2021 deadline.
-
A Satsuma Pharmaceuticals, Inc. 10-Q filed 2021-08-10
“as well as a new STS101 pivotal Phase 3 SUMMIT efficacy trial, or SUMMIT trial, of STS101 5.2 mg that we initiated in June 2021” ✓ confirmed on the page
-
A Satsuma Pharmaceuticals, Inc. 10-K filed 2022-03-15
“a Phase 3 efficacy trial (the SUMMIT trial), which we initiated in June 2021 and is currently ongoing” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Second STS101 Phase 3 efficacy trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Satsuma Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C692830-024821 · Corrections policy